From private incentives to public health need: rethinking research and development for pandemic preparedness

Els Torreele, Daniel Wolfe, Michel Kazatchkine, Amadou Sall, Kiat Ruxrungtham, Joseph Robert Anderson Fitchett, Joanne Liu, Gary Kobinger, Claudia Vaca-González, Carolina Gómez, Petro Terblanche, Soumya Swaminathan, Piero Olliaro, Helen Clark

Research output: Contribution to journalReview articlepeer-review


Pandemic preparedness and response have relied primarily on market dynamics to drive development and availability of new health products. Building on calls for transformation, we propose a new value proposition that instead prioritises equity from the research and development (R&D) stage and that strengthens capacity to control outbreaks when and where they occur. Key elements include regional R&D hubs free to adapt well established technology platforms, and independent clinical trials networks working with researchers, regulators, and health authorities to better study questions of comparative benefit and real-world efficacy. Realising these changes requires a shift in emphasis: from pandemic response to outbreak control, from one-size-fits-all economies of scale to R&D and manufacture for local need, from de novo product development to last-mile innovation through adaptation of existing technologies, and from proprietary, competitive R&D to open science and financing for the common good that supports collective management and sharing of technology and know-how.

Original languageEnglish (US)
Pages (from-to)e1658-e1666
JournalThe Lancet Global Health
Issue number10
StatePublished - Oct 2023

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'From private incentives to public health need: rethinking research and development for pandemic preparedness'. Together they form a unique fingerprint.

Cite this